In fact, we recently demonstrated that chemical inhibition of FABP4 could be a therapeutic strategy against insulin resistance, diabetes mellitus (DM), fatty liver disease, and atherosclerosis in experimental models[9]. Here, FABP4 is linked to Insulin resistance.